scholarly journals American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate

2020 ◽  
Vol 183 (2) ◽  
pp. 389-391 ◽  
Author(s):  
A. Senchyna ◽  
S. Simon ◽  
H. Cissé ◽  
M. Ginouves ◽  
G. Prevot ◽  
...  
Keyword(s):  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
French Guiana ◽  
Liposomal Amphotericin B ◽  
Meglumine Antimoniate ◽  
American Cutaneous Leishmaniasis ◽  
Retrospective Comparison

Cutaneous leishmaniasis in a Japanese returnee from West Africa successfully treated with liposomal amphotericin B

2011 ◽  
Vol 38 (11) ◽  
pp. 1062-1065 ◽  
Author(s):  
Misaki ONO ◽  
Kenzo TAKAHASHI ◽  
Kiyohito TAIRA ◽  
Hirosi UEZATO ◽  
Saori TAKAMURA ◽  
...  
Keyword(s):  
West Africa ◽  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B

scholarly journals Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B

2018 ◽  
Vol 62 (10) ◽  
Author(s):  
Gert-Jan Wijnant ◽  
Katrien Van Bocxlaer ◽  
Amanda Fortes Francisco ◽  
Vanessa Yardley ◽  
Andy Harris ◽  
...  
Keyword(s):  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Skin Inflammation ◽  
Skin Lesions ◽  
Disease Stage ◽  
Liposomal Amphotericin B ◽  
Local Skin ◽  
Content Type ◽  
Tissue Inflammation

ABSTRACTDisfiguring skin lesions caused by several species of theLeishmaniaparasite characterize cutaneous leishmaniasis (CL). Successful treatment of CL with intravenous (i.v.) liposomal amphotericin B (LAmB) relies on the presence of adequate antibiotic concentrations at the dermal site of infection within the inflamed skin. Here, we have investigated the impact of the local skin inflammation on the pharmacokinetics (PK) and efficacy of LAmB in two murine models of localized CL (Leishmania majorandLeishmania mexicana) at three different stages of disease (papule, initial nodule, and established nodule). Twenty-four hours after the administration of one 25 mg/kg of body weight LAmB (i.v.) dose to infected BALB/c mice (n= 5), drug accumulation in the skin was found to be dependent on the causative parasite species (L. major>L. mexicana) and the disease stage (papule > initial nodule > established nodule > healthy skin). Elevated tissue drug levels were associated with increased vascular permeability (Evans blue assay) and macrophage infiltration (histomorphometry) in the infected skin, two pathophysiological parameters linked to tissue inflammation. After identical treatment of CL in the two models with 5 × 25 mg/kg LAmB (i.v.), intralesional drug concentrations and reductions in lesion size and parasite load (quantitative PCR [qPCR]) were all ≥2-fold higher forL. majorthan forL. mexicana. In conclusion, drug penetration of LAmB into CL skin lesions could depend on the disease stage and the causativeLeishmaniaspecies due to the influence of local tissue inflammation.

Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin B

2005 ◽  
Vol 51 (5) ◽  
pp. e261-e264 ◽  
Author(s):  
A. Paradisi ◽  
R. Capizzi ◽  
A. Zampetti ◽  
I. Proietti ◽  
C. De Simone ◽  
...  
Keyword(s):  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Immunocompetent Patient ◽  
Liposomal Amphotericin B

Recidivans cutaneous leishmaniasis unresponsive to liposomal amphotericin B (AmBisomeR)

2000 ◽  
Vol 14 (1) ◽  
pp. 11-13 ◽  
Author(s):  
Kamer Gunduz ◽  
Sule Afsar ◽  
Semin Ayhan ◽  
Ali Riza Kandiloglu ◽  
Aylin Turel ◽  
...  
Keyword(s):  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B
Sign in / Sign up

Export Citation Format

Share Document